Type: Blog Post
Identifier:
Q7V5BLE6
Description
Compulsory licences should be issued to roll out generic versions of innovative HCV drugs. Only generic competition can push down the extortionate prices of these lifesaving medicines, while placing equitable access and public interest before monopolistic pharma companies’ business strategies, Daniele Dionisio argues.